Alzheimer’s disease is one of the most challenging brain disorders of our time. It slowly damages memory, thinking, and daily functioning, and it affects millions of people worldwide.
As populations age, the number of people living with Alzheimer’s is expected to rise sharply. One of the biggest challenges in fighting the disease is detecting it early and studying it across different populations.
Until now, most reliable tests for Alzheimer’s have required expensive brain scans or uncomfortable spinal fluid procedures, which are not easy to access for many people around the world.
A new international study has now shown that this situation could change dramatically. Researchers have demonstrated that key signs of Alzheimer’s disease can be detected using a simple finger-prick blood sample.
Even more importantly, the blood sample can be collected at home, dried on a card, and mailed to a laboratory without refrigeration or special handling. This discovery could open the door to Alzheimer’s research and screening on a global scale.
The study was led by Banner Health in the United States, working closely with scientists from the University of Exeter Medical School in the United Kingdom and several other European research centers.
The results were published in the journal Nature Medicine. This is the first large study to confirm that finger-prick blood samples can reliably measure Alzheimer’s-related markers in a real-world research setting.
Alzheimer’s disease is usually confirmed using brain imaging scans or tests of spinal fluid taken through a needle in the lower back. These methods are costly, invasive, and often limited to large hospitals with specialized equipment. In recent years, blood tests have emerged as a promising alternative.
Certain proteins in the blood change as Alzheimer’s develops, and measuring these proteins can give scientists important clues about what is happening in the brain. However, most blood tests still require trained staff, clinic visits, and careful handling of samples, which limits who can take part in research studies.
To address this problem, researchers launched the DROP-AD project. This project involved seven medical centers across Europe, including major universities in Gothenburg and Exeter. In total, 337 people took part in the study.
The goal was to see whether a few drops of blood collected from a fingertip and dried on special paper could accurately reflect changes linked to Alzheimer’s disease and brain damage.
The results were highly encouraging. The researchers focused on a protein called p-tau217, which is strongly linked to Alzheimer’s disease. Levels of this protein measured from finger-prick samples closely matched results from standard blood tests taken from a vein.
The test was able to identify Alzheimer’s-related changes seen in spinal fluid with an accuracy of about 86 percent. Two other important markers, known as GFAP and NfL, were also successfully measured and showed strong agreement with traditional testing methods.
One of the most important parts of the study took place at the University of Exeter Medical School. This was the only site where participants collected their own blood samples at home. People watched a short demonstration, read clear instructions, and then performed the finger-prick test themselves without help from medical staff.
The results showed that self-collected samples were just as reliable as those collected in clinical settings. This finding is crucial because it proves that large numbers of people could take part in research without traveling to hospitals or research centers.
The implications of this work are far-reaching. By removing the need for specialized clinics, this approach could allow researchers to include people from rural areas, low-income regions, and communities that have historically been left out of Alzheimer’s research.
It could also make it easier to recruit participants for clinical trials and to monitor changes in the brain over time. People with conditions such as Down syndrome, who face a higher risk of Alzheimer’s disease, could also benefit from easier access to testing.
Researchers also note that this method could be useful beyond Alzheimer’s disease. The marker NfL, which was successfully measured in the study, is linked to nerve damage in many brain conditions. This means the same technique could support research into Parkinson’s disease, multiple sclerosis, ALS, and brain injuries.
While the findings are exciting, the researchers stress that this method is not yet ready for clinical use. More studies are needed to confirm the results in larger and more diverse populations and to determine how the test could be used safely and responsibly in real-world health care.
At this stage, the finger-prick test is best seen as a powerful research tool rather than a diagnostic test for patients.
Overall, this study represents a major step forward in Alzheimer’s research. It shows that reliable brain disease markers can be measured using a simple, low-cost method that people can use at home. The findings suggest that future research could become more inclusive, more global, and more efficient.
If further studies confirm these results, this approach could reshape how scientists study Alzheimer’s disease and how early changes in the brain are detected. By lowering barriers to participation, the finger-prick test has the potential to accelerate discoveries and bring the world closer to better prevention and treatment strategies.
If you care about Alzheimer’s, please read studies about Vitamin D deficiency linked to Alzheimer’s, vascular dementia, and Oral cannabis extract may help reduce Alzheimer’s symptoms.
For more information about brain health, please see recent studies about Vitamin B9 deficiency linked to higher dementia risk, and results showing flavonoid-rich foods could improve survival in Parkinson’s disease.
Copyright © 2025 Knowridge Science Report. All rights reserved.
